Tissue-specific shRNA delivery: a novel approach for gene therapy in cancer

Connect Tissue Res. 2008;49(3):265-9. doi: 10.1080/03008200802147845.

Abstract

A novel tissue-specific shRNA delivery system has been developed using cre-lox technology. Conditionally silenced pSico vector containing oligonucleotides of CD44shRNA and tissue-specific promoter-driven Cre-recombinase expression vector are packaged into transferrin-coated nanoparticles that can deliver shRNA into specific tumors. This system has strong potential in cancer therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / therapy
  • Cell Line, Tumor
  • Colonic Neoplasms / metabolism
  • Colonic Neoplasms / therapy
  • Female
  • Gene Transfer Techniques
  • Genetic Therapy / methods*
  • Genetic Vectors
  • Humans
  • Hyaluronan Receptors / genetics*
  • Hyaluronan Receptors / metabolism
  • Hyaluronic Acid / metabolism*
  • Integrases / metabolism
  • Male
  • Nanoparticles
  • Neoplasms / metabolism
  • Neoplasms / therapy*
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / therapy
  • RNA Interference*
  • RNA, Small Interfering / genetics*
  • Transfection

Substances

  • Hyaluronan Receptors
  • RNA, Small Interfering
  • Hyaluronic Acid
  • Cre recombinase
  • Integrases